Charles River Labs quietly continues its critical work to save lives see more
CHARLESTON, S.C. (AP) — It’s one of the stranger, lesser-known aspects of U.S. health care — the striking, milky-blue blood of horseshoe crabs is a critical component of tests to ensure injectable medications such as coronavirus vaccines aren’t contaminated.
To obtain it, harvesters bring many thousands of the creatures to laboratories to be bled each year, and then return them to the sea — a practice that has drawn criticism from conservationists because some don’t survive the process.
The blood, which is blue due to its copper content, is coveted for proteins used to create the LAL test, a process used to screen medical products for bacteria. Synthetic alternatives aren’t widely accepted by the health care industry and haven’t been approved federally, leaving the crabs as the only domestic source of this key ingredient.
Many of these crabs are harvested along the coast of South Carolina, where Gov. Henry McMaster promoted the niche industry as key to the development of a domestic medical supply chain, while also noting that environmental concerns should be explored.
“We don’t want to have to depend on foreign countries for a lot of reasons, including national security, so it’s good to see this company thriving in the United States,” McMaster told The Associated Press. He spoke this month during a visit to Charles River Laboratories at its Charleston facilities, to which AP was granted rare access. “We want to do everything we can to onshore all of these critical operations.”
Horseshoe crabs — aquatic arthropods shaped like helmets with long tails — are more akin to scorpions than crabs, and older than dinosaurs. They’ve been scurrying along the brackish floors of coastal waters for hundreds of millions of years. Their eggs are considered a primary fat source for more than a dozen species of migratory shore birds, according to South Carolina’s Department of Natural Resources.
Their value to avoiding infection emerged after scientists researching their immune response injected bacteria into horseshoe crabs in the 1950s. They ultimately developed the LAL test, and the technique has been used since the 1970s to keep medical materials and supplies free of bacteria.
Their biomedical use has been on the rise, with 464,482 crabs brought to biomedical facilities in 2018, according to the Atlantic States Marine Fisheries Commission.
In South Carolina, that’s done only by Charles River, a Massachusetts-based company that tests 55% of the world’s injectables and medical devices — like IV bags, dialysis solutions and even surgical cleaning wipes, according to company officials.
“We are almost the last line of defense before these drugs leave the manufacturing area and make it to a patient,” senior vice president Foster Jordan told McMaster. “If it touches your blood, it’s been tested by LAL. And, more than likely, it’s been tested by us.”
Charles River employs local fishermen to harvest the crabs by hand, a process governed by wildlife officials that can only happen during a small annual window, when the creatures come ashore to spawn.
Contractors bring them to the company’s bleeding facilities, then return them to the waters from which they came. During a year, Jordan said his harvesters can bring in 100,000 to 150,000 horseshoe crabs, and still can’t satisfy the growing demand.
“We need more, though,” Jordan told McMaster, adding that his company is working with the state to open up more harvesting areas. “The population’s steady. ... We need access to more beaches, to get more crabs.”
The practice is not without its critics, some of whom have argued that bleeding the crabs and hauling them back and forth is harmful. According to the National Oceanic and Atmospheric Administration, 10% to 15% of harvested crabs die during the process.
The International Union for Conservation of Nature listed the species overall as “vulnerable,” noting decreasing numbers as of a 2016 assessment. The Atlantic States Marine Fisheries Commission listed 2019 stock as “good” in the Southeast, but “poor” in areas around New York.
Conservationists sued last year, accusing the U.S. Fish and Wildlife Service of shirking its duty to protect areas including South Carolina’s Cape Romain National Wildlife Refuge by allowing horseshoe crab harvesting. They argued that taking out the crabs affects other species in the protected area. A federal judge temporarily halted the harvest, but was reversed following Charles River’s appeal.
The environmental groups asked to withdraw their complaint this month after federal officials imposed a permitting process for any commercial activity in the refuge, including horseshoe harvesting, beginning Aug. 15. Even if such permits are denied, Jordan told McMaster that only 20% of its harvest came from the refuge, with most coming from further down the South Carolina coast.
There is a synthetic alternative to the horseshoe crab blood, but it hasn’t been widely accepted in the U.S., and meanwhile, Charles River’s international competitors are making synthetics and also pressing for U.S. Food and Drug Administration approval, which Jordan said could hamper domestic efforts like his own.
“My mission is to make sure that any competitor that comes into the United States, from China or any of these other producers, has to go through the same regulatory process that we had to go through, to make sure that it’s safe,” Jordan said. “If all these synthetics start coming in from other countries, we’re going to lose the protection that we’ve had for all these years, and the safety, and the control of the drug supply.”
“We want to have as much stuff made here as we can,” McMaster said in response.
As for the environmental concerns, the governor said maintaining a healthy balance between scientific demands and the state’s ecosystems, which bolster a significant portion of South Carolina’s tourism economy, is paramount.
“It’s like a house of cards. You pull out one part, and the rest of it will fall,” McMaster said. “So I think we have to be very careful, and be sure that any company, any business, any activity, whether it’s commercial or otherwise, meets whatever requirements are there to protect the species — birds, horseshoe crabs, any sort of life.”
Lou Kennedy and Nephron Team step up for SC again see more
Glove Plant Will Shore Up Domestic Supply Chain, Reduce American Dependence on Foreign Sources of Medical-Grade Gloves & Create New Jobs
WEST COLUMBIA, S.C. – During a celebration attended by strategic partners, business leaders and public officials, Nephron Pharmaceuticals Corporation CEO Lou Kennedy and Governor Henry McMaster today announced the opening of Nephron Nitrile, a plant that will produce American-made, medical-grade nitrile gloves.
The announcement is the latest Nephron expansion on the sprawling company campus located at Saxe-Gotha Industrial Park in Lexington County.
Nephron Nitrile – which will be headquartered in more than 400,000 square feet of space in the Kennedy Innovation Complex – represents an investment of more than $100 million in the Midlands. The plant will generate 250 jobs for the area.
“This is a historic day for our company, and, we believe, for South Carolina,” said Kennedy. “Over the course of the last year, we have poured every bit of creativity, energy and resources we have at our disposal into doing our part, as a proud Made-in-America manufacturer, to respond to an unprecedented crisis. Nephron Nitrile is the latest part of our ongoing effort to make South Carolina the nationwide example for effectively responding to America’s needs, this time by shoring up the domestic supply chain.”
Kennedy and the governor, along with the entire Nephron team, have made reducing the American dependence on foreign sources of critical health care-related items, such as personal protective equipment (PPE) and lifesaving medications, a top priority. Kennedy joined the governor in April when he announced an executive order to safeguard South Carolina from supply chain disruptions, such as those caused by countries like China, experienced during the COVID-19 pandemic by working to manufacture even more essential, life-saving products in South Carolina.
Now, just months later, Kennedy and her team at Nephron are stepping up once again. In doing the work on the front end of the announcement to secure partnerships with trusted companies to provide raw materials, machinery and technology, Nephron is in position to make a significant difference in bolstering the PPE supply chain by early 2022.
“It is critical that South Carolina lead the charge in bringing the production of life-saving medications and supplies back home to the United States,” said Governor McMaster. “After last year’s supply chain disruptions caused by the COVID-19 pandemic, I announced a new initiative aimed at expanding recruitment efforts of pharmaceutical and medical supply manufacturers in the Palmetto State. Nephron Pharmaceuticals Corporation’s continued investment in South Carolina and our people will go a long way toward creating much-needed independence in this industry. This great company continues to show that we have the talent and the ability to do anything we put our minds to, right here in South Carolina.”
Last July, Kennedy announced an investment of $215 million for Lexington County, bringing 380 new full-time jobs to the area by 2024, and adding new office, warehouse and vaccine production space. This announcement included the establishment of the Kennedy Innovation Complex, home of Nephron Nitrile, and these projects are ahead of schedule. Since re-locating company headquarters to Lexington County from Orlando, Nephron has invested more than a half billion dollars in the region, creating almost 2,000 full and part time jobs.
“Lexington County is beyond excited to say congratulations again to Nephron Pharmaceuticals,” said Lexington County Council Chairman M. Todd Cullum. “The county is enthusiastic about this announcement as much or more than the company’s original announcement to locate in Lexington County. Their investment in hard assets and jobs is second to none in South Carolina. Nephron’s partnership with Lexington County has been tremendous in helping to improve the quality of life in our county and the region. We can’t wait to see what the future holds for this extraordinary company.”
A West Columbia, S.C.-based company, Nephron develops and produces safe, affordable generic inhalation solutions and suspension products. The company also operates an industry-leading 503B Outsourcing Facility division which produces pre-filled sterile syringes, luer-lock vials, IV bottles and IV bags for hospitals across America, in an effort to alleviate drug shortage needs. Nephron launched a CLIA-certified diagnostics lab last year where it tests people for COVID-19 and administers vaccinations.
For more information regarding Nephron Nitrile, including orders and partnerships, please email: NephronNitrile@nephronpharm.com.
Medical data company relocating headquarters in the Upstate, creating 10 new jobs see more
COLUMBIA, S.C. – Sync.MD, a medical data company, today announced plans to establish operations in Anderson County, creating 10 new jobs.
Founded in 2015, Sync.MD specializes in the mobile data storage of health and medical records. The company’s patented technology enables users to securely store complete and current health care records and update information on smartphones for seamless sharing of medical records with health care providers. Sync.MD helps solve the problem of connecting otherwise incompatible medical records systems, as well as meet the specific needs of veterans or those who require specialized care. Sync.MD’s innovative technology enables higher-quality coordination of care, which means better outcomes and reduced costs for patients.
Located in Anderson, South Carolina, Sync.MD’s new facility will increase the company’s capacity to meet growing demand.
Operations are expected to be online by fall 2021. Individuals interested in joining the Sync.MD team should email or call (864) 260-1061 for additional information.
"Sync.MD is excited to continue its growth with a relocation to Anderson County. We are incredibly grateful for the assistance of the South Carolina Department of Commerce and Anderson County officials throughout our site selection process, and we are looking forward to what we know will be a fruitful partnership going forward." -Sync.MD CEO Eugene Luskin
“We are thrilled to add Sync.MD to the South Carolina family. This announcement is great news for Anderson County, and we look forward to the great work this company will accomplish.” -Gov. Henry McMaster
“It’s always exciting to see a company choose South Carolina as their new home. We celebrate Sync.MD’s decision to invest and create new jobs in Anderson County and look forward to watching them grow in the future.” -Secretary of Commerce Bobby Hitt
"I am very excited for Sync.MD to establish operations in Anderson County. The jobs that are moving here are high-paying tech jobs, and more will be created in the future. When I first met with Sync.MD’s leadership years ago, I told them South Carolina has a great business environment, and that we would welcome the chance to help them grow. I am thrilled that Sync.MD will be providing services to our veterans and their customers around the world from right here in Anderson." -U.S. Congressman Jeff Duncan
“We are excited to welcome software company Sync.MD to Anderson County’s new soft-landing economic development space. Sync.MD exemplifies the type of innovative business we continually seek to attract to further diversify and support the local economy.” -Anderson County Council Chairman Tommy Dunn
“Sync.MD landing in the Upstate represents areas where the Upstate is poised for growth — life sciences, technology and market entry into a landing pad space. We look forward to seeing this innovative digital health solutions provider grow in our region.” -Upstate SC Alliance President & CEO John Lummus
FIVE FAST FACTS
- Sync.MD is establishing operations in Anderson County.
- The company is creating 10 new jobs.
- Sync.MD is a medical data company.
- Located in Anderson, S.C.
- Individuals interested in joining the Sync.MD team should email or call (864) 260-1061 for additional information.
Lightsey nominated to succeed Bobby Hitt as leader of SC Commerce Department see more
Gov. Henry McMaster announced Thursday, June 17, 2021, that he has nominated longtime South Carolina business executive Harry M. Lightsey III to be the next secretary of the South Carolina Department of Commerce.
Lightsey - a former top executive with Bellsouth, AT&T and General Motors - will succeed Bobby Hitt, who is retiring in the fall.
“Harry Lightsey has been a fixture in South Carolina’s business community for decades, and I’m confident that with the vast experience he will be bringing to the Department of Commerce, South Carolina will keep winning,” McMaster said. “Our state will have the workforce, infrastructure, intellectual capital, environmental assets and the quality of life necessary to compete – both nationally and globally – for jobs and investment.”
A fixture in South Carolina’s business community for decades, Lightsey served in top executive leadership roles for major corporations in South Carolina and across the nation.
Notably, he served as the president of BellSouth Telecommunications for South Carolina prior to its merger with AT&T, afterward becoming president for AT&T’s Southeast region.
Following his 26 years in the telecommunications industry, Lightsey joined the General Motors Corporation where he directed the legacy automaker’s federal government affairs operation, as well as their emerging technologies, OnStar and infotainment divisions.
Lightsey is a principal with Hawksbill Advisors - a subsidiary of Hawksbill Group. He has also served as a member of the board of directors of the Federal Reserve Bank in Richmond, Virginia.
“It would be my distinct honor and privilege to have the opportunity to serve as South Carolina’s Secretary of Commerce,” Lightsey said. “In addition to bringing new businesses into our state, I believe we have a role to play in helping our established businesses thrive and transform when necessary.
“As the governor has said, South Carolina needs an educated, trained, and skilled workforce so that we can compete nationally and globally for jobs and capital investment. Our workers will need to develop new skills to adjust to ever changing technological advances. I am excited about the opportunities to usher in a new era that enhances the quality of life for all South Carolinians.”
Fluent in Japanese, Lightsey is a 1978 graduate of Princeton University, and a 1981 graduate of the University of South Carolina School of Law. (For a copy of Lightsey’s full resume, click here.)
Lightsey, 65, is a native of Columbia, S.C. and is married with two adult children.
The governor’s nomination follows Hitt’s decision to retire after over 10 years of service to the state of South Carolina.
Originally appointed by former Gov. Nikki Haley in her first year as governor, Hitt’s years at the helm of the S.C. Department of Commerce have been marked by significant success in recruiting businesses from around the world to invest in the state.
“What team South Carolina has done over the last 10 plus years – creating economic opportunities and improving lives within our borders – is quite simply remarkable,” Hitt said. “I couldn’t be prouder of our accomplishments and also couldn’t feel more confident in the direction moving forward. Harry Lightsey’s extensive background aligns with Commerce’s mission and will provide meaningful context for engagement in the state’s business community.”
“Secretary Hitt’s leadership at the Department of Commerce has helped usher in an era of unprecedented economic growth in our state,” McMaster said. “He has helped solidify Team South Carolina’s global brand for automotive, aerospace, and tire manufacturing and their international export. While we are sorry to see his time at the agency come to an end, we are immeasurably grateful for his service and for the bright future we know our state will realize, in no small part, because of his leadership.”
During Hitt’s time as secretary, South Carolina has announced 1,141 projects, 129,373 new jobs, and over $35.8 billion in capital investment, including three new automotive manufacturers – Volvo Cars, Mercedes Benz-Vans, and Arrival.
Additionally, manufacturing employment grew from 16.7 percent from 209,491 in January 2011 to 244,476 in December 2020. South Carolina remains the largest exporter of passenger vehicles, tires, and ball bearings.
Hitt will continue to serve in his current capacity until the S.C. Senate confirms the governor’s nomination of Lightsey.
Gov. Henry McMaster Announces New Economic Development Initiative to Expand Recruitment of Pharmaceutical Companies, Shore Up Emergency Supply ChainsGovernor provides strong support for growing life sciences in state see more
In front of several dozen business leaders, executives and media members at Bausch and Lomb in Greenville today, Governor Henry McMaster today issued Executive Order 2021-17, which directs the Department of Commerce to enhance recruitment efforts of pharmaceutical and medical supply manufacturers in South Carolina and directs state agencies to focus procurement efforts of medicines, medical devices, and medical supplies on those made in South Carolina. The new initiative will safeguard South Carolina from supply chain disruptions experienced during the COVID-19 pandemic by working to manufacture even more essential, life-saving products in South Carolina.
“This last year has made it very clear that relying on China for life-saving medical supplies is a risk we can no longer afford, and South Carolina can lead the way when it comes to bringing the manufacturing of those products back home to the United States," said Gov. Henry McMaster. “By successfully recruiting pharmaceutical and medical manufacturing companies to invest and locate here, we will bring good, high-paying jobs for our people and reliable access to the critical supplies we may need in an emergency.”
The Department of Commerce will work directly with SCBIO on the new initiative. SC BIO is a statewide, not-for-profit life sciences and economic development organization formed to promote and expand South Carolina’s life sciences industry.
“As a major driver and diversification of South Carolina’s growing economy, the surging impact, reach and significance of the multi-billion dollar life sciences industry in our state certainly warrants the strategic emphasis being placed on it by Governor McMaster,” noted SCBIO President and CEO Sam Konduros. “We’re honored by the Governor‘s profound support, and this bold Executive Order further demonstrates his ongoing commitment to empower our statewide mission to build, advance and grow the life sciences and pharmaceutical industry in the Palmetto State like never before.”
To further investment and job creation from businesses in the pharmaceutical industry, the governor’s Order directs the South Carolina Department of Commerce to:
- Prioritize and enhance ongoing economic development and recruitment efforts by identifying, encouraging, and incentivizing pharmaceutical and medical supply manufacturers, both international and domestic, to locate research, development, and production facilities within the State of South Carolina.
- Develop and execute international and domestic marketing campaigns that promote the State of South Carolina as a global leader in this Sector.
- Facilitate, assist, and incentivize growth, expansion, investment, and employment opportunities at existing businesses and industries in the Sector located within the State of South Carolina.
- Identify and advocate for statutory or regulatory changes or enhancements to the state’s existing economic development mechanisms for new business and industry investment or expansion in the Sector.
The Order also directs the Department of Commerce to review its existing operations and organizational structure to determine whether any changes would assist with the recruitment of pharmaceutical companies and to recommend any needed modifications to the General Assembly, if statutory authority is required to make them.
To further ensure supply chain security, the governor’s Order calls upon state agencies to prioritize South Carolina-made products in the procurement of medicines, medical devices, and medical supplies. The move will benefit existing businesses and will give Commerce another resource to attract additional life science investment into South Carolina.
SCBIO, industry honored by Governor during record-setting virtual annual conference see more
South Carolina Gov. Henry McMaster
Proclamation – Feb. 15, 2021
WHEREAS, South Carolina has cultivated a cutting-edge life sciences sector with an annual economic impact of more than $12 billion dollars; and
WHEREAS, more than 800 firms and over 43,000 professionals are directly involved in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotechnology products; and
WHEREAS, since 2017, the life sciences sector has become South Carolina's fastest- growing industry, with employment growing at double the rate of South Carolina's economy as a whole; and
WHEREAS, SCBIO is the organization exclusively focused on attracting new life science sector jobs and investment to South Carolina; and
WHEREAS, during the COVID-19 pandemic, more than 100 life sciences organizations across South Carolina worked together to support and promote the procurement and distribution of personal protective equipment, support and implement COVID-19 testing and expedite health solutions for our citizens; and
WHEREAS, in collaboration with the South Carolina Department of Commerce and SCBIO, South Carolina's economic development recruitment efforts shall include an enhanced emphasis and focus on attracting, building, advancing, innovating and growing existing and new life sciences businesses in the state.
NOW, THEREFORE, I, Henry McMaster, Governor of the great State of South Carolina, do hereby proclaim February 15-19, 2021, as
SCBIO LIFE SCIENCE WEEK
throughout the state and encourage all South Carolinians to recognize and appreciate the many contributions of the life sciences industry to South Carolina's health and economic prosperity.
Governor McMaster Issues Proclamation Recognizing South Carolina Life Sciences Week to Celebrate State’s Fastest-Growing IndustryGovernor salutes industry during record-setting SC Life Sciences Conference see more
SOUTH CAROLINA – February 16, 2021 – In recognition of the importance of the life sciences industry in South Carolina, Governor Henry McMaster today issued a proclamation recognizing February 15-19, 2021 as South Carolina Life Sciences Week in the Palmetto State.
Governor McMaster made the announcement just steps from where SCBIO organizers were putting the finishing touches on Day 1 of the largest-ever life sciences gathering held – virtually of course -- in the state. A record 600 registrants from across America and around the globe are attending the virtual SCBIO gathering of South Carolina’s life sciences community – and celebrating the contributions of its 800+ organizations in helping America and the world overcome the challenging COVID-19 pandemic.
“South Carolina has developed a strong reputation as an emerging leader in the life sciences,” said Governor McMaster. “Our innovative companies and exceptional workforce are key drivers in strengthening our economy and creating new opportunities for South Carolinians. With an incredible pace of growth in the industry here, we know that the life sciences will continue to play a critically important role in our state’s economic success for generations to come.”
Governor McMaster made the proclamation in downtown Greenville, in the heart of the county which possesses the state’s largest concentration of life sciences companies, although the industry boasts life sciences organizations in 42 of South Carolina’s 46 counties currently. Governor McMaster was flanked by leadership and Board members of SCBIO, South Carolina’s investor-driven economic development organization exclusively focused on building, advancing, innovating and growing the life sciences industry in the state.
Life sciences has a $12 billion economic impact in the Palmetto State, with more than 800 firms involved and over 43,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotechnology products. It also represents a significant economic development focus for the state, with strong life science recruiting initiatives led by the South Carolina Department of Commerce and other regional economic development teams.
South Carolina life sciences has seen a doubling of firms and 40% increase in life sciences’ direct employment since 2017, which combine to make it the fastest growing industry sector in the state, according to recent data provided by Dr. Joseph Von Nessen, the state's research economist and noted economic development expert with the Moore School of Business at the University of South Carolina.
“Life sciences is a major driver of South Carolina’s economy today, and this conference is testament to the industry’s surging impact, reach and rapidly rising economic significance in our state and country,” noted SCBIO President and CEO Sam Konduros. “We’re honored by Governor McMaster’s recognition, and appreciate his personal support for the contributions that life sciences are making to improve quality of life, care and economic standing for South Carolina citizens.”
For additional information on SCBIO or to register for SCBIO 2021, visit www.SCBIO.org.
Nephron Pharmaceuticals Corporation expanding operations again, adding 380 jobs, $215.8 million investment$215.8 million investment will create 380 new jobs in Lexington County, SC see more
Nephron Pharmaceuticals Corporation (Nephron), a global leader in the production of generic respiratory medications and blow-fill-seal contract manufacturing, today announced plans to expand operations in Lexington County. The company's $215.8 million investment will create 380 new jobs.
A West Columbia, S.C.-based company, Nephron develops and produces safe, affordable generic inhalation solutions and suspension products, including those used to treat severe respiratory distress symptoms associated with COVID-19.
The company also operates an industry-leading 503B Outsourcing Facility division which produces pre-filled sterile syringes and IV bags for hospitals across America, in an effort to alleviate drug shortage needs. Nephron fills the needs of patients and health care professionals as they arise nationwide, and recently opened a CLIA-certified diagnostics lab.
Headquartered at 4500 12th Street in West Columbia, Nephron’s expansion will add new offices, a new warehouse and production space at its campus in Saxe-Gotha Industrial Park.
The expansion is expected to be completed by Q1 of 2021. Individuals interested in joining the Nephron team should visit https://www.nephronpharm.com/careers.
The Coordinating Council for Economic Development has approved job development credits related to this project.
“The Nephron family is extraordinarily grateful for the opportunity to grow in South Carolina. Thanks to our partnerships with state and local officials, and the trust they have placed in us, we have been able to provide life-saving medications to patients around the world and establish ourselves as the global leader in what we do. We are proud of these achievements and more, and we know our best days are ahead of us. That is what makes this latest announcement so special.” -Nephron Owner & CEO Lou Kennedy
“We are proud to have Nephron Pharmaceuticals in South Carolina. Since coming here they have become an integral part of the community, and recently have been vital in the fight against COVID-19. This new investment of more than $215 million creating 380 new jobs in Lexington County is a great win for Team South Carolina.” -Gov. Henry McMaster
“Nephron is a longtime steward of South Carolina’s business community, and we congratulate them on their continued growth within our state. Today’s announcement is yet another big win for South Carolina, our people and our burgeoning life sciences sector.” -Secretary of Commerce Bobby Hitt
“We are excited to continue to partner with such an innovative and forward-thinking company like Nephron Pharmaceuticals. We know that Lexington County is a great place to establish and grow a business, and Nephron’s continued success is a testament to good government-business relations.” -Lexington County Council Chairman Scott Whetstone
FIVE FAST FACTS
• Nephron Pharmaceuticals Corporation (Nephron) is expanding operations in Lexington County.
• The $215.8 million investment is projected to create 380 new jobs.
• Nephron is a global leader in the production of generic respiratory medications and blow-fill-seal contract manufacturing.
• Headquartered at 4500 12th Street in West Columbia, S.C.
• Individuals interested in joining the Nephron team should visit https://www.nephronpharm.com/careers.
Zylö Therapeutics is locating new operations in Greenville County, SC. see more
GREENVILLE, S.C. – Zylö Therapeutics, a developer of state-of-the-art technology for the pharmaceutical industry, is locating new operations in Greenville County. The company is expected to create 30 new jobs.
Zylö Therapeutics has developed an innovative sustained-release drug-delivery system that delivers traditionally hard-to-deliver therapeutic agents through topical administration. With more than 10 years of research and development, the second generation of this technology continues to improve, providing 24-hour sustained release of a variety of agents, including nitric oxide, curcumin, lidocaine and more.
Zylö Therapeutics is headquartered at the NEXT on Main facility at 101 North Main Street in Greenville, S.C. NEXT is a program of the Greenville Chamber of Commerce that currently supports more than 100 knowledge-based companies in Upstate South Carolina.
Zylö Therapeutics’ operations will soon include a lab facility, where formulation and product development work will be performed. Those interested in joining the Zylö Therapeutics team should visit www.zylotherapeutics.com for more information.
“With the bulk of our scientists and advisors located in the Northeast corridor, we considered a variety of alternative locations, but Greenville represents a wonderful balance of small-town feel, sophistication, high growth and vibrancy. In addition, the city offers a wealth of start-up resources that will assuredly work to our advantage over time.” – Zylö Therapeutics CEO Scott Pancoast
“To see a company like Zylö Therapeutics choose to invest in our state and our people is an important sign to the business community around the world that South Carolina is the place to be. We’ve worked hard to create a pro-business environment and cultivate a highly-trained workforce, and those efforts continue to pay off.” –Gov. Henry McMaster
“The success of South Carolina’s booming life sciences industry continues to impress, and I congratulate Zylö Therapeutics on today’s tremendous announcement. Over the last two decades, we’ve seen a major transformation in South Carolina’s economy, and innovative companies like Zylö Therapeutics are responsible for it.” –Secretary of Commerce Bobby Hitt
“Greenville County encourages growth in the bioscience sector of our economy. We are proud to welcome Zylö Therapeutics to Greenville as part of our vibrant bioscience community that is pioneering state-of-the-art technologies at the forefront of modern medicine. We wish great success for Zylö Therapeutics.” –Greenville County Council Chairman H.G. “Butch” Kirven Jr.
“Greenville has become increasingly attractive to industry leaders in next-generation medical care, as innovative companies like Zylö Therapeutics seek environments that can help connect resources, support emerging technologies and supply a dedicated workforce. The City of Greenville is thrilled to welcome Zylö to our vibrant downtown and we look forward to being a part of their company’s growth.” –City of Greenville Mayor Knox White
“We are excited to welcome Zylö Therapeutics as the newest member of NEXT and the Greenville startup community. This high-impact, knowledge-based company further strengthens the more-than-150 companies within this vibrant, entrepreneurial ecosystem.” –NEXT CEO John Moore
FIVE FAST FACTS
- Zylö Therapeutics is locating new operations in Greenville County.
- The start-up is projected to create 30 new jobs.
- Zylö Therapeutics is a developer of patented, state-of-the-art technology for the pharmaceutical industry.
- Headquartered in Suite 315 at 101 North Main Street in Greenville, S.C., the company’s operations will include a laboratory facility focused on formulation and product development.
- Those interested in joining the Zylö Therapeutics team should visit www.zylotherapeutics.com for more information.